Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::ALK status confers therapeutic sensitivity to Brigatinib in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Service Executive:
Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.